United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 5,060 shares of the company's stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $237.52, for a total transaction of $1,201,851.20. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,877.60. The sale was disclosed in a legal filing with the SEC, which is available through this link.
United Therapeutics Price Performance
NASDAQ UTHR opened at $237.04 on Wednesday. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The firm has a market capitalization of $11.16 billion, a P/E ratio of 11.95 and a beta of 0.52. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average price of $228.15 and a 200-day moving average price of $228.08.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics's revenue was up 25.1% on a year-over-year basis. During the same period last year, the company earned $2.67 earnings per share. Equities research analysts anticipate that United Therapeutics Co. will post 23.46 earnings per share for the current year.
Institutional Trading of United Therapeutics
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Institutional investors and hedge funds have recently made changes to their positions in the business. Rise Advisors LLC bought a new stake in shares of United Therapeutics during the first quarter worth $32,000. Atlas Capital Advisors LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth $51,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 49.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 65 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth $43,000. Finally, Neo Ivy Capital Management bought a new stake in shares of United Therapeutics during the second quarter worth $48,000. 94.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have weighed in on UTHR shares. HC Wainwright reissued a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, April 3rd. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They issued an "outperform" rating and a $330.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of "Buy" and an average price target of $294.40.
View Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
